Literature DB >> 21148524

Editor's choice: Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer.

Matthew R Watts1, Peter C Taylor, Vitali Sintchenko, Clair M Whelan, Robert H Farnsworth, Philip Jones, Peter Jelfs, David Carr, Hazel Goldberg.   

Abstract

We report a case of sepsis from Mycobacterium bovis Bacillus Calmette-Guérin (BCG) with low-level isoniazid resistance following intravesical treatment for bladder cancer. Isoniazid resistance in BCG has therapeutic implications when it causes infections after intravesical instillation. For these circumstances, we propose some modifications to existing treatment guidelines for BCG infection.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21148524     DOI： 10.1093/cid/ciq002

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  4 in total

Review 1.  Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.

Authors:  Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

2.  "BCGitis": A rare case of tuberculous epididymo-orchitis following intravesical Bacillus Calmette-Guérin therapy.

Authors:  Virginie Demers; Vincent Pelsser
Journal:  J Radiol Case Rep       Date:  2012-11-01

3.  Disseminated Mycobacterium bovis Infection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder.

Authors:  Fatehi Elzein; Nada Albogami; Mustafa Saad; Nazik El Tayeb; Abdullah Alghamdi; Ghaleb Elyamany
Journal:  Clin Med Insights Case Rep       Date:  2016-08-16

4.  Phenotypic and Genotypic Drug Susceptibility Assessment of Mycobacterium bovis Bacillus Calmette-Guérin Clinical Strains.

Authors:  Maria Carolina Sisco; Marlei Gomes da Silva; Luciana Distasio de Carvalho; Carlos Eduardo Dias Campos; Paulo Cesar De Souza Caldas; Beatriz Lopez; Claudia Argüelles; Ana Carolina Carvalho; Jacobus de Waard; Philip Suffys; Rafael Silva Duarte
Journal:  Infect Drug Resist       Date:  2021-02-05       Impact factor: 4.003
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.